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Objectives:We aimed to quantify the impact of fluoroquinolone resistance on the clinical outcome of paediatric
shigellosis patients treated with fluoroquinolones in southern Vietnam. Such information is important to inform
therapeutic management for infections caused by this increasingly drug-resistant pathogen, responsible for high
morbidity and mortality in young children globally.
Methods: Clinical information and bacterial isolates were derived from a randomized controlled trial comparing
gatifloxacin with ciprofloxacin for the treatment of paediatric shigellosis. Time–kill experiments were performed
to evaluate the impact of MIC on the in vitro growth of Shigella and Cox regression modelling was used to com-
pare clinical outcome between treatments and Shigella species.
Results: Shigella flexneri patients treated with gatifloxacin had significantly worse outcomes than those treated
with ciprofloxacin. However, the MICs of fluoroquinolones were not significantly associated with poorer outcome.
The presence of S83L and A87T mutations in the gyrA gene significantly increased MICs of fluoroquinolones.
Finally, elevated MICs and the presence of the qnrS gene allowed Shigella to replicate efficiently in vitro in high
concentrations of ciprofloxacin.
Conclusions: We found that below the CLSI breakpoint, there was no association between MIC and clinical out-
come in paediatric shigellosis infections. However, S. flexneri patients had worse clinical outcomes when treated
with gatifloxacin in this study regardless of MIC. Additionally, Shigella harbouring the qnrS gene are able to
replicate efficiently in high concentrations of ciprofloxacin and we hypothesize that such strains possess a
competitive advantage against fluoroquinolone-susceptible strains due to enhanced shedding and transmission.
Introduction
The Gram-negative bacterial genus Shigella are the most com-
mon cause of bacillary dysentery globally.1,2 Of the four species
within the genus, Shigella flexneri and Shigella sonnei predomin-
ate, with S. sonnei currently replacing S. flexneri as the major spe-
cies in industrializing regions.3 The WHO currently recommends
the fluoroquinolone ciprofloxacin as the first-line therapy, with
ceftriaxone and pivmecillinam as secondary alternatives.4
However, antimicrobial resistance (AMR) within the species is
becoming more prevalent and may present a significant chal-
lenge for therapeutic management.
The primary target of the fluoroquinolones is the DNA gyrase, a
typeIItopoisomeraseessential forDNAreplicationandtranscription.5
Mutations in the gyrA gene increase the MICs of fluoroquinolones for
Shigella and other Enterobacteriaceae.6–9 Plasmid-mediated quin-
olone resistance (PMQR) genes can also be acquired, such as the qnr
genes that encode pentapeptide repeat proteins that bind to and
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protect the DNA gyrase and topoisomerase from the action of fluor-
oquinolones.10 Complete ciprofloxacin resistance (MIC ≥4 mg/L11)
has been recently reported in both domestic and imported S. sonnei
isolates in the USA, Vietnam and elsewhere.12–14
The rapid evolution and global dissemination of fluoroquino-
lone resistance in the Enterobacteriaceae hampers effective
treatment and is, therefore, a major threat to human health.15
The WHO has explicitly listed fluoroquinolone-resistant Shigella
as one of its top concerns in the current international focus on
AMR.15 AMR can lead to inappropriate choice of antimicrobial for
initial therapy and may force clinicians to choose more toxic or
more expensive antimicrobials.16 Furthermore, patients infected
with fluoroquinolone-resistant Campylobacter and Salmonella
infections in the USA have been shown to have a longer duration
of diarrhoea compared with those infected with fluoroquinolone-
susceptible strains.17,18 Although one study from Vietnam sug-
gested a correlation between increasing AMR levels in S. sonnei
and clinical severity,19 no rigorous evaluation of the impact of
fluoroquinolone resistance or presence of gyrAmutations on clin-
ical outcome of Shigella infections has been performed.
Here, we aimed to quantify the effect of fluoroquinolone
choice, fluoroquinolone susceptibility and presence of gyrAmuta-
tions on fever clearance time (FCT) and total duration of illness in
children with S. flexneri and S. sonnei infections in Vietnam.
Additionally, we sought to compare the severity and AMR profiles
between Shigella species as well as investigate the effect of ele-
vated MIC and gyrA mutations on the in vitro activity of Shigella.
Understanding the dynamics of increasing MICs of commonly
used fluoroquinolones and clinical patient outcome in industrial-
izing locations is important as it allows clinicians to be better
informed when prescribing therapies for what can often be severe
infections in young children.
Methods
Patient population
The source data for this study was a randomized controlled trial. The
protocol (including justification for use of gatifloxacin) and results for
this trial have been described previously in detail.20 Briefly, 500 children
were enrolled into an open-label, randomized clinical trial comparing
3 day regimens of gatifloxacin (10 mg/kg/day orally in one dose) and
ciprofloxacin (30 mg/kg/day orally in two doses) for the treatment of shi-
gellosis in southern Vietnam. Children were enrolled between 2006 and
2009 at the Hospital for Tropical Diseases in Ho Chi Minh City and at Huu
Nghi Hospital in Dong Thap province. Inclusion criteria included age
,15 years and a history of bloody or mucoid stools in the 72 h prior to
admission to hospital. Exclusion criteria included severe infection (shock,
jaundice and extensive gastrointestinal bleeding), known treatment with
a fluoroquinolone during the episode and concomitant infection requiring
antimicrobial therapy.
Study procedures
Daily case report forms detailing clinical presentation were administered
for each patient during the period of hospitalization. A case report form
was also administered at a follow-up visit that occurred 7 days after dis-
charge. Clinical failure was defined as fever (≥37.88C) or the persistence of
any signs or symptoms after 120 h of start of treatment (vomiting,
abdominal pain or tenesmus with/without three or more loose stools
with/without blood and/or mucus). Total duration of symptoms was
defined as the time from admission until cessation of all listed symptoms.
Microbiological failure was defined as a positive stool culture for the ori-
ginal infecting pathogen after day 3 of the antimicrobial therapy. FCT
was defined as the time from admission until temperature was ≤37.88C
for ≥48 h.
Stool samples were collected on admission and standard microbio-
logical techniques were employed to identify Shigella and Salmonella iso-
lates.20 Antimicrobial susceptibility testingwas performed bydisc diffusion
followingmethods prescribed by the CLSI.11 MICs were calculated by Etest
as per the manufacturer’s instructions (AB Biodisk, Sweden). Strains that
were identified as resistant to ceftriaxone were subjected to further
phenotypic tests to confirm ESBL production using discs containing only
cefotaxime (30 mg) and both cefotaxime and ceftazidime combined
with clavulanic acid (10 mg), according to current CLSI guidelines.11
Genomic DNA extraction, PCR and sequencing
Genomic DNA was purified using the Wizard genomic DNA extraction kit
(Promega, USA) as recommended by the manufacturer. Extracted DNA
was subjected to PCR targeting known mutation regions on gyrA and
parC genes and the PMQR genes qnrA, qnrB, qnrC, qnrS, aac(6 ′)-Ib-cr
and qepA. Primer sequences were GyrA_F: 5′-CGACCTTGCGAGAGAAAT-3′,
GyrA_R: 5′-GTTCCATCAGCCCTTCAA-3′,21 ParC_F: 5′-AAACCTGTTCAGCGCC
GCATT-3′ and ParC_R: 5′-GTGGTGCCGTTAAGCAAA-3′.22 The primers for
the PMQR genes were as previously published.23–25 Taq DNA polymerase
supplied by Bioline (UK) was used for the amplifications. Concentrations
of reagents were as recommended by the manufacturers. PCR amplifica-
tions were performed under the following conditions: 1 cycle of 958C for
5 min followed by 35 cycles of 958C for 30 s, 558C for 30 s and 728C for
1 min. PCR amplicons were sequenced using an ABI 3700 system (ABI,
USA) and sequencing reactions were prepared as recommended by
the manufacturer. Resulting sequences were analysed using Bioedit
software.
Time–kill analyses
One isolate from each mutation group was selected for in vitro time–kill
experiments, all were S. flexneri isolates: (i) no gyrAmutation, ciprofloxacin
MIC 0.023 mg/L and gatifloxacin MIC 0.023 mg/L; (ii) gyrAmutation A87T,
ciprofloxacin MIC 0.094 mg/L and gatifloxacin MIC 0.125 mg/L; (iii) gyrA
mutation S83L, ciprofloxacin MIC 0.19 mg/L and gatifloxacin MIC
0.19 mg/L; and (iv) gyrAmutation S83L, ciprofloxacinMIC 8 mg/Land gati-
floxacin MIC 6 mg/L with qnrS gene. Strains were grown overnight in
Mueller–Hinton (MH) broth. S. flexneri isolates were chosen due to the lar-
ger range of MICs of fluoroquinolones compared with those for S. sonnei.
The bacterial cultures were diluted 1:1000 into 10 mL of fresh MH broth.
The inoculation was incubated at 378C with a circular agitation speed of
150 rpm for 1.5 h. The cultures were mixed with either ciprofloxacin or
gatifloxacin, which had been prepared in MH broth to achieve the final vol-
ume of 20 mL of the desired concentration of drugs. Controls for each
mutant were identical cultures but without supplementary antimicrobials.
Bacterial cells were counted at time 0 and 30 min, 1 h, 2 h, 4 h, 6 h, 12 h
and 24 h after incubation with antimicrobials. The experiment was per-
formed in replicates of nine for each selected isolate. The limit of detection
was 10 cfu/mL.26
Statistical analyses
All data were analysed in STATA v13 (TX, USA). Plots were made in R
(R Foundation for Statistical Computing, Austria) using the ggplot2 pack-
age.27 Continuous data were compared between groups using the
Kruskal–Wallis test. Categorical group data were compared using x2 or
Fisher’s exact test. For MICs that were recorded as ‘greater than X’ or
‘less than X’, these values were converted into 2X and X/2, respectively.
Logistic regression was used to evaluate the relationship between
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treatment arm, MICs and overall failure, with interaction between drug
and MIC evaluated through the likelihood ratio test. We analysed the
time to event endpoints of FCT and total duration of symptoms using
Cox regression models. Interaction between species and treatment arm
as well as MIC and treatment within species were evaluated using the like-
lihood ratio test. Age was included a priori as a covariate in all models.
Ethics approval
This study was approved by the institutional ethics review boards of the
Hospital for Tropical Diseases and Huu Nghi Hospital and the Oxford
Tropical Research Ethics Committee (OxTREC: 010-06). Written informed con-
sent from the parent or guardian was required for enrolment into the trial.
Results
Baseline clinical and demographic characteristics
Of the 500 children enrolled, 6 withdrew after randomization, leav-
ing 494 for analysis. A total of 107/494 (22%) enrolled trial patients
were stool culture positive for Shigella spp. Of these, 72 (67%) were
S. sonnei, 33 (31%) were S. flexneri and 2 (2%) were Shigella boydii.
As shown in Table 1, S. sonnei patients were slightly younger
(median: 30 months, IQR: 20–43) than S. flexneri patients (median:
36 months, IQR: 22–60) and were more likely to report a greater
number ofmucoid stools in the first 24 h after admission compared
with S. flexneri patients. S. sonnei patients also had slightly elevated
Table 1. Baseline demographic and clinical characteristics of all patients, S. sonnei patients and S. flexneri patients
Characteristic All patients, n¼494 S. sonnei patients, n¼72 S. flexneri patients, n¼33 Pa
Site, n (%)
Ho Chi Minh City 194 (39.3) 48 (66.7) 20 (60.6) 0.546
Dong Thap 300 (60.7) 24 (33.3) 13 (39.4)
Study drug, n (%)
ciprofloxacin 245 (49.6) 34 (47.2) 12 (36.4) 0.298
gatifloxacin 248 (50.2) 38 (52.8) 21 (63.6)
Age (months), median (IQR) 19 (10.5–32) 30 (20–43) 36 (22–60) 0.062
Male, n (%) 291 (58.9) 40 (55.6) 14 (42.4) 0.211
Nutritional status, n (%)
overweight 4 (0.8) 1 (1.4) 0 (0) 0.089
normal 363 (73.5) 60 (83.3) 26 (78.8)
malnutrition I 93 (18.8) 10 (13.9) 3 (9.1)
malnutrition II 29 (5.9) 1 (1.4) 4 (12.1)
malnutrition III 5 (1.0) 0 (0) 0 (0)
Prior to admission
illness duration (h), median (IQR) 24 (16–48) 20 (12–33) 19 (12–24) 0.785
fever (≥37.88C), n (%) 429 (87.4) 68 (94.4) 33 (100) 0.167
history of febrile convulsions, n (%) 40 (8.1) 6 (8.3) 2 (6.1) 1.000
history of diarrhoea with blood, n (%) 210 (42.5) 24 (33.3) 11 (33.3) 1.000
history of mucoid diarrhoea without blood, n (%) 284 (57.5) 48 (66.7) 22 (66.7) 1.000
vomiting, n (%) 204 (41.3) 34 (47.2) 16 (48.5) 0.904
abdominal pain, n (%) 365/492 (74.2) 52 (72.2) 30 (90.9) 0.041
tenesmus, n (%) 339/490 (69.2) 45/71 (63.4) 22 (66.7) 0.745
Within 24 h of admission
mucoid diarrhoea without blood, n (%) 370 (74.9) 59 (81.9) 22 (66.7) 0.083
number of mucoid stools/24 h, median (IQR) 3 (0–6) 4 (2–10) 2 (0–5) 0.028
diarrhoea with blood, n (%) 445 (90.1) 70 (97.2) 33 (100) 0.334
number of bloody stools/24 h, median (IQR) 1 (1–5) 3 (1–6) 3 (1–9) 0.187
maximum number of episodes/24 h, median (IQR) 6 (3–10) 8 (3–11) 8 (4–10) 0.806
white blood cells in stool (cells/HPF), n (%)
0 214/479 (44.7) 14/68 (20.6) 8/32 (25.0) 0.754
1–10 79/479 (16.5) 11/68 (16.2) 4/32 (12.5)
11–20 42/479 (8.8) 5/68 (7.4) 4/32 (12.5)
21–30 104/479 (21.7) 26/68 (38.2) 9/32 (28.1)
.30 40/479 (8.4) 12/68 (17.6) 7/32 (21.9)
white cell count×109/L, median (IQR) 11.3 (8–14.9) 13.5 (10.7–16.9) 10.2 (7.3–16.4) 0.071
HPF, high power field.
aP value comparing S. sonnei and S. flexneri by Kruskal–Wallis test for continuous data or x2/Fisher’s exact test for categorical data.
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white cell counts (median 13.5×109/L, IQR: 10.7–16.9) compared
with S. flexneri patients (median: 10.2×109/L, IQR: 7.3–16.4).
S. flexneri patients, however, were more likely to report abdominal
pain (91%) prior to admission than S. sonnei patients (72%).
Antimicrobial susceptibility
As shown in Table 2, S. flexneri isolates were more likely to have
higher MICs against the fluoroquinolones (with the exception of
ofloxacin) compared to S. sonnei. In fact, S.flexnerihadsignificantly
higherMICs of all testedantimicrobialswith theexceptionof ceftriax-
one, forwhichS. sonneihadsignificantlyelevatedMICsoverS. flexneri
(P,0.001, Kruskal–Wallis test) (Figure 1). Overall, S. flexneri isolates
were more likely to be MDR (defined here as non-susceptible to
more than three antimicrobial classes) (28/33, 85%) compared
with S. sonnei (22/72, 31%) (P,0.001, Fisher’s exact test) while
S. sonnei isolates were more likely to exhibit an ESBL phenotype
(14/72, 19%) than S. flexneri (1/33, 3%) (P¼0.033, Fisher’s exact
test) (Figure S1, available as Supplementary data at JAC Online).
Finally, 3/33 (9%) of the tested S. flexneri isolates and 1/72 (1%) of
tested S. sonnei isolates were PCR amplification positive for the qnrS
Table 2. Comparison of MICs of fluoroquinolones for S. sonnei and
S. flexneri isolates
Antimicrobial
S. sonnei MIC
(mg/L), n¼72
S. flexneri MIC
(mg/L), n¼33 Pa
Nalidixic acid
median (range) 48 (0.09–512) 512 (1–512) 0.046
geometric mean 35.3 68.4
Ciprofloxacin
median (range) 0.064 (0.01–0.25) 0.125 (0.01–8) 0.011
geometric mean 0.05 0.08
Gatifloxacin
median (range) 0.094 (0.01–0.25) 0.19 (0.01–6) 0.008
geometric mean 0.06 0.09
Ofloxacin
median (range) 0.38 (0.05–1) 0.38 (0.05–16) 0.135
geometric mean 0.25 0.3
aP value comparing MIC between species by Kruskal–Wallis test.
Ciprofloxacin Gatifloxacin Gentamicin
Naladixic acid Ofloxacin Tetracycline
Ampicillin Ceftriaxone Chloramphenicol
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Figure 1. MICs (mg/L) of a range of antimicrobials for the Shigella isolates in this study (log2 scale). Box plots show the median (black line across each
box) and the 5th and 95th percentiles. MICs for S. sonnei are shown in dark grey and MICs for S. flexneri are in light grey. The broken line in each plot
represents the current CLSI breakpoint for resistance.11
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gene.NoparCmutations,qnrA,qnrB,aac(6′)-Ib-crorqepAgeneswere
identified within any of the Shigella isolates.
The MICs of fluoroquinolones were highly correlated for both
S. sonnei and S. flexneri (P,0.001 for all correlations). When nor-
malized to the mean of the current CLSI resistance breakpoint
(ciprofloxacin: ≥4 mg/L, gatifloxacin: ≥8 mg/L),11 both S. flexneri
and S. sonnei had higher relativemedian log2 MICs of ciprofloxacin
than of gatifloxacin (P,0.001 in both cases, Kruskal–Wallis test of
z-score) (Figure S2). Furthermore, the presence of a single gyrA
mutation and/or the qnrS gene dramatically increased the MICs
of fluoroquinolones for both S. sonnei and S. flexneri (Table 3
and Figure S3).
Time–kill curves
Mutations in gyrA, the presence of qnrS and elevated MICs of
ciprofloxacin substantially increased the ability of S. flexneri to
replicate in the presence of ciprofloxacin (Figure 2). The S. flexneri
strain lacking a gyrAmutation with a low MIC of ciprofloxacin was
rapidly killed by the antimicrobial (Figure 2). While the isolate with
the gyrA mutation A87T (Figure 2) was still effectively killed at
higher concentrations of ciprofloxacin, bacterial growth remained
elevated at lower concentrations compared with the S. flexneri
without a gyrA mutation. The S83L mutation (Figure 2) reduced
the bactericidal activity of ciprofloxacin even further, with
cfu/mL reduced by .5 logs at high concentrations. Finally, the
S. flexneri isolate with an S83L gyrA mutation, qnrS gene and
MIC of ciprofloxacin of 8 mg/L (Figure 2) was able to grow in the
presence of all tested concentrations of ciprofloxacin during
the first hour post-inoculation, with growth falling by 2 logs
only within the second hour post-inoculation. Further, the
concentration-dependent killing effect was lost with the qnrS
mutant, as the 2× to 16×MIC curves exhibited almost identical
profiles. The same pattern was observed with the corresponding
gatifloxacin time–kill curve (data not shown).
Clinical outcome in shigellosis with fluoroquinolone
therapy
Overall, there were 8 (7.6%) failures among the 105 Shigella
cases, all of which were S. sonnei (8/72, 11%). Two of these
cases were microbiological failures and six were classified as clin-
ical failures. Overall failure amongst the S. sonnei isolates was not
significantly associated with either treatment drug (OR: 0.5, 95%
CI: 0.1–2.3, P¼0.37) or MIC of nalidixic acid, ciprofloxacin, gati-
floxacin or ofloxacin. Additionally, although 5/8 (63%) failures
had the A87T gyrA mutation and 1/8 (13%) had the S83L gyrA
mutation, there was no significant effect of a gyrA mutation on
failure (OR: 1.03, 95% CI: 0.3–3.3, P¼0.96).
Overall, the FCTs of S. sonnei and S. flexneri were not signifi-
cantly different (HR: 1.2, 95% CI: 0.8–1.8, P¼0.47). There was
no difference in FCT between the two species in the ciprofloxacin
arm (HR: 0.73, 95% CI: 0.4–1.4, P¼0.355) and although S. flexneri
patients had moderately longer FCTs in the gatifloxacin arm
(median: 27 h, IQR: 16–48) compared with S. sonnei (median:
12 h, IQR: 3–24), the difference was not statistically significant
after controlling for age (HR: 1.52, 95% CI: 0.9–2.7, P¼0.13)
(Figure 3a and b). Notably, the FCTs of S. flexneri treated with gati-
floxacin (median: 27 h, IQR: 16–48) were significantly longer than
for S. flexneri patients treated with ciprofloxacin (median: 15, IQR:
4–22) (HR: 0.40, 95% CI: 0.2–0.9, P¼0.02). Similar patterns were
observed for total duration of symptoms (Figure 3c and d), as
S. flexneri patients treated with gatifloxacin (median: 60 h, IQR:
4–72) had significantly longer duration of symptoms compared
with S. flexneri patients treated with ciprofloxacin (median: 48 h,
IQR: 33–54) (HR: 0.39, 95% CI: 0.2–0.9, P¼0.02). No difference in
total duration of symptoms was detected between the treatment
arms for S. sonnei patients. The presence of gyrA mutations did
not have a significant effect on either FCT or total duration of
symptoms (P.0.05 for both comparisons).
When evaluating the effect of MICs on FCT and duration of
symptoms, we found a significant interaction between treatment
arm and gatifloxacin and ciprofloxacin MICs for S. flexneri patients
(P,0.03 in all comparisons). Although increasing ciprofloxacin
MICs appeared to be associated with increased FCTand symptom
duration in S. flexneri patients treated with gatifloxacin (Figure 4),
these trends were not statistically significant (effect of log2 cipro-
floxacin MICon (i) FCT: HR: 0.92 (95% CI: 0.8–1.1, P¼0.33); and (ii)
symptom duration: HR: 0.86 (95% CI: 0.7–1.1, P¼0.15). This pat-
tern was comparable for the gatifloxacin MIC (data not shown).
Finally, there was no significant effect of MIC of either antimicro-
bial in the ciprofloxacin treatment arm or amongst S. sonnei
patients in either treatment arm.
Discussion
The bacterial genus Shigella are a considerable public health prob-
lem, responsible for .7 million disability-adjusted life years and
Table 3. MICs of fluoroquinolones for S. sonnei and S. flexneri by gyrA mutation and qnrS gene, median (range)
Antimicrobial
S. sonnei MIC (mg/L) S. flexneri MIC (mg/L)
no mutation,
n¼19
A87T,
n¼40
S83L,
n¼9
S83L/qnrS,
n¼1
no mutation,
n¼11
S83L,
n¼16
qnrS,
n¼1
S83L/qnrS,
n¼2
Nalidixic acid 1.50 (0.09–3.0) 64 (32–512) 96 (64–512) 512 2.0 (1.0–4.0) 512 (512–512) 1.50 512 (512–512)
Ciprofloxacin 0.01 (0.01–0.02) 0.06 (0.05–0.13) 0.19 (0.13–0.25) 0.25 0.02 (0.01–0.05) 0.19 (0.09–0.25) 0.01 4.13 (0.25–8.0)
Gatifloxacin 0.01 (0.01–0.13) 0.09 (0.06–0.13) 0.19 (0.13–0.25) 0.19 0.01 (0.01–0.06) 0.19 (0.13–0.38) 0.01 3.13 (0.25–6.0)
Ofloxacin 0.06 (0.05–0.09) 0.38 (0.25–0.50) 0.75 (0.5–1.0) 0.75 0.09 (0.05–0.19) 0.5 (0.38–1.0) 0.05 8.25 (0.5–16)
All pairwise comparisons within species across antimicrobials were statistically significantly different by Kruskal–Wallis tests (all P,0.001) and all
pairwise comparisons of A87T and S83L (regardless of qnrS) in S. sonnei were statistically significantly different (P,0.001), except for A87T versus
S83L for nalidixic acid (P¼0.03), by Kruskal–Wallis test.
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.100000 deaths annually, which aremainly concentrated in chil-
dren living in developing countries.1,2,28,29 The current drug of
choice for treating Shigella infections is ciprofloxacin. However,
fluoroquinolone resistance is threatening to make the manage-
ment of this diarrhoeal pathogen even more challenging.15
Here, we aimed to quantify the impact of treatment choice,
fluoroquinolone MIC and presence of gyrA mutations on clinical
outcome of paediatric S. flexneri and S. sonnei patients treated
with fluoroquinolones. We additionally evaluated the ability of
Shigella strains of varying resistance profiles to grow in the pres-
ence of ciprofloxacin through time–kill experiments rather than
single timepoint MIC testing.
While we hypothesized that poorer clinical outcome was asso-
ciated with higher fluoroquinolone MIC and observed this trend in
our data, we were unable to conclude that such relationships were
statistically significant. This is likely due to small numbers of
patients and relatively low MICs for isolates collected during the
time period (2006–09). Mutations in gyrA were not found to be
associated with an inferior clinical outcome in either species,
although S83Land A87Tmutations did result in isolateswith higher
MICs of fluoroquinolones. We hypothesize that fluoroquinolone
MICs may play a greater role in clinical outcome above the CLSI
breakpoint as we have shown conclusively that below the current
breakpoints, MIC does not have a significant impact on patient out-
come. Therefore, we surmise that the current CLSI breakpoints for
fluoroquinolones are appropriate for Shigella therapy.
We identified differences in clinical response between both the
Shigella species and treatment arms. S. flexneri patients had sig-
nificantly longer FCTs and duration of symptoms when treated
with gatifloxacin compared with ciprofloxacin. Gatifloxacin is pre-
sumed to be a more efficacious drug than ciprofloxacin,30 yet
S. flexneri isolates were more likely to have higher MICs of cipro-
floxacin (relative to the CLSI breakpoint) compared with gatifloxa-
cin. In the absence of additional data assessing the penetration of
None: 0.023 mg/L Asp87Tyr: 0.094 mg/L
Ser83Leu: 0.19 mg/L Ser83Leu: 8 mg/L, qnrS
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Figure 2. Time–kill curves of S. flexneri gyrA (qnrS) genotypes on exposure to increasing concentrations of ciprofloxacin. Plots showing the mean time–
kills of S. flexneri isolates grown with increasing concentrations of ciprofloxacin based on the MIC for the original isolate at different timepoints
post-inoculation (log2 scale). The S. flexneri isolates are: (a) no gyrA mutation, ciprofloxacin MIC¼0.023 mg/L; (b) gyrA mutation A87T, ciprofloxacin
MIC¼0.094 mg/L; (c) gyrA mutation S83L, ciprofloxacin MIC¼0.19 mg/L; and (d) gyrA mutation S83L, ciprofloxacin MIC¼8 mg/L with the qnrS gene.
The broken line represents the limit of detection for the assay (10 cfu/mL).
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gatifloxacin into the epithelial cells lining the gastrointestinal
tract, we hypothesize this difference between antimicrobials in
S. flexneri patients may be due to more effective killing of the
local commensal gut microbiota by gatifloxacin, which may
allow Shigella to more efficiently invade the gut tissue.31 – 33
Further investigation into the effects of fluoroquinolones on the
gut microbiota are required.
The time–kill experiments clearly demonstrate that an ele-
vated MIC, and most notably presence of the combination of a
qnrS gene and a gyrA mutation, allows Shigella to replicate effi-
ciently in high concentrations of fluoroquinolone. We hypothesize
that such enhanced persistence in the gastrointestinal tract dur-
ing therapy endows fluoroquinolone-resistant Shigella with a
competitive advantage over fluoroquinolone-susceptible strains.
AMR Shigella are not only more likely to survive therapy but also
to be shed and further transmitted in the community, over time
replacing the fluoroquinolone-susceptible strains. For example,
the acquisition of chloramphenicol resistance is understood to have
afforded certain clones of Salmonella enterica serovar Typhimurium
the ability to replace susceptible strains in sub-Saharan Africa over
several years.34 Furthermore, there is limited evidence that suggests
that an elevatedMICof nalidixic acid lengthens the duration of excre-
tion of Shigella.35
The time–kill results also suggest that acquisition of qnrS in
addition to an S83L mutation in gyrA may lead to a loss of
concentration-dependent killing by fluoroquinolones. This has
been observed previously in Escherichia coli with the qnrS gene36
and may relate to the mechanism of action of qnrS whereby
peptides bind to the DNA gyrase and block fluoroquinolone activ-
ity. Although higher concentrations of fluoroquinolones are gener-
ally preferred in therapy to reduce the likelihood of development
of resistant strains,37,38 qnrS mutants may not respond to high
doses given our time–kill observations. Therefore, combination
therapy in patients with qnrS-positive Shigella infections could
be warranted. Further pharmacodynamic work on qnrS mutants
in the Enterobacteriaceae is clearly required.
This study has some limitations. First, FCT and duration of
symptoms may not be the most appropriate measures of clinical
outcome. We therefore may have under- or overestimated
the effect of fluoroquinolone resistance on patient outcome.
Second, we had a limited range of fluoroquinoloneMICs and a lim-
ited number of treatment failures, whichmade it difficult to better
evaluate trends in the isolates with elevated MICs or in those that
failed treatment. It will be important to repeat this work with con-
temporary strains as higher levels of fluoroquinolone resistance
will permit such an investigation.39 Furthermore, collection of
longitudinal stool samples after treatment is warranted to under-
stand the effect of resistance on excretion duration. Nonetheless,
thework presented here offers the first rigorous analysis of fluoro-
quinolone resistance on patient outcome to our knowledge and
fills an important gap in the knowledge of this increasingly
antimicrobial-resistant pathogen.
We conclude that below the CLSI breakpoint, MICs of fluoroqui-
nolones do not strongly impact patient outcome in shigellosis.
Therefore, the current CLSI breakpoints are warranted for Shigella
infections. However, our data suggest that the choice of
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Figure 3. Clinical outcome comparison between S. sonnei and S. flexneri infections treated with fluoroquinolones. Unadjusted Kaplan–Meier plots
showing FCT in hours in patients treated with (a) ciprofloxacin (n¼46) and (b) gatifloxacin (n¼59). Total duration of symptoms in days is shown in
patients treated with (c) ciprofloxacin and (d) gatifloxacin. S. sonnei are shown in dark grey and S. flexneri are shown in light grey.
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fluoroquinolone is important in the management of Shigella infec-
tions, as S. flexneri patients treatedwith gatifloxacin had poorer out-
comes compared with those treated with ciprofloxacin. Further, we
demonstrate that qnrS-harbouring Shigella are able to grow effect-
ively in vitro at high concentrations of ciprofloxacin and hypothesize
that fluoroquinolone-resistant strains outcompete susceptible
strains, as they are maintained during therapy, shed and therefore
more likely to be transmitted in the community. Continued evalu-
ation of the impact of fluoroquinolone resistance on the clinical out-
come of Shigella patients over time is critical to help inform clinical
treatment decisions for diarrhoeal infections.
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